LONDON, November 21, 2022–(BUSINESS WIRE)–November is Men’s Health Awareness Month with Movember and International Men’s Day being recognised globally, both highlighting the importance of supporting the health and wellbeing of men. To mark these key calendar dates, International SOS shares guidance on how organisations can increase awareness of physical and mental health issues among men and encourage early detection and treatment of disease.
Globally, life expectancy among men is lower than that of women1 and attitudes towards healthcare and how people perceive preventive measures to be effective can differ by sex. For instance, on average, men (75.9%) were found to be less likely than women (84.2%) to believe that COVID-19 measures including social distancing and mask-wearing were effective for preventing the spread of the virus. When facing the same disease, men are less likely to take a proactive approach to seeking healthcare than women2.
Dr Rodrigo-Rodriguez Fernandez, Global Health Advisor, Wellness & Mental Health, EMEA Practice, Consulting & Solutions at International SOS, said "Common health conditions affecting men include heart disease, diabetes, lung and prostate cancer. In fact, more than 1.4 million men worldwide are diagnosed with prostate cancer each year3. Many factors can contribute to these conditions including lifestyle choices, diet and cardiovascular fitness. Regular health check-ups can help detect some medical issues in the early stages and promote positive lifestyle changes to improve wellbeing."
Dr Rodrigo-Rodriguez Fernandez continued "The notions and stereotypes of masculinity may also be harmful to men’s health. The stigma attached to illnesses and men perceiving illness as a weakness are often the reasons why men are not vocal about their health concerns. Given these traditional societal pressures and stigma, there is a crucial need for continued focus on men’s health and wellbeing across organisations and workplaces. Employers should create healthy and equitable work environments and facilitate access to medical and counselling support that is gender sensitive."
While both men and women can experience their share of mental health challenges, in general, men are less likely to disclose their mental health issues to family members or friends4. With a high number of the working population likely to be experiencing such issues, employers are ideally placed to drive change and empower men to seek the support and treatment they need.
Employers can provide expert counselling with high level of anonymity, training for team leads to recognise signs of mental ill-health and create a safe space for conversation. This type of support can help to improve the lives of the many men quietly struggling with mental health. A simple act such as being involved in, and showing support for, awareness events such as Movember and International Men’s Day also helps organisations create a workplace culture in which conversations about mental health issues are encouraged and supported.
Top tips for organisations to support men’s health and wellbeing in the workplace:
Encourage regular health screening to help detect some medical issues in the early stages.
Provide employees with anonymous access to mental health and wellbeing support that is gender sensitive.
Create safe spaces for employees to have conversation around men’s mental health issues and talk about their mental health.
Make employee wellbeing a core part of line manager job responsibilities and provide appropriate time, resources and training for them to recognise early signs and symptoms of mental-ill health.
Be involved in global events such as International Men’s Day and Movember and highlight the focus on improving men’s health and wellbeing.
About the International SOS Group of Companies
The International SOS Group of Companies is in the business of saving lives, protecting your global workforce from health and security threats. Wherever you are, we deliver customised health, security risk management and wellbeing solutions to fuel your growth and productivity. In the event of extreme weather, an epidemic or a security incident, we provide an immediate response providing peace of mind. Our innovative technology and medical and security expertise focus on prevention, offering real-time, actionable insights and on-the-ground quality delivery. We help protect your people, your organisation's reputation, as well as support your compliance reporting needs. By partnering with us, organisations can fulfil their Duty of Care responsibilities, while empowering business resilience, continuity and sustainability.
Founded in 1985, the International SOS Group, headquartered in London & Singapore, is trusted by 9,500 organisations, including the majority of the Fortune Global 500 as well as mid-size enterprises, governments, educational institutions, and NGOs. 13,000 multi-cultural security, medical, logistics and digital experts stand by you to provide support & assistance from over 1,000 locations in 90 countries, 24/7, 365 days.
To protect your workforce, we are at your fingertips: www.internationalsos.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005061/en/
Alexis Harding, Group Head of PR & Communications, London
E: [email protected]
There's a cliché that the average person gains 10 pounds during the holiday season. While that exact number might not be entirely accurate, according to research, it's still common for people to pack on some extra pounds thanks to all those big meals, tasty treats, and adult beverages. Lucky for you, we're here to share three ridiculously easy rules to help you keep the weight off over the holidays.Unfortunately, some people become so terrified of gaining weight that they deny themselves all the
Veru (NASDAQ: VERU), a biopharmaceutical company that looks for novel cancer therapies, particularly in breast cancer or prostate cancer, saw its shares drop 10.33% on Monday. The company's stock already lost $10 a share two weeks ago when a Food and Drug Administration (FDA) advisory panel voted 8-5 against approving sabizabulin, Veru's COVID-19 oral therapy, via the Emergency Use Authorization route. It's not the last word, but the FDA usually agrees with advisory panels' votes.
The biopharmaceutical company specializes in cancer therapies. Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical trial as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence found in an abnormal chromosome 22, often seen in people with certain types of leukemia.
Is Pfizer stock a buy after surging on Moderna's omicron-focused booster shot data? Is PFE stock a buy right now?
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Data supports moving ahead with NASH clinical studies… Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has multiple clinical development programs underway. ORMD-0801, ORMP’s lead development candidate, is being tested in diabetes in dual concurrent Phase 3 studies of ORMD-0801 for the treatment of T2D and in NASH. We believe Oramed’s multiple
The study of the clitoris was able to be done thanks to gender affirming surgeries.
Be informed this open enrollment season.
Biotech giant Bristol Myers (BMY) outperforms the industry and the S&P 500 Index as Eliquis and Opdivo maintain momentum despite generic competition for Revlimid.
Why the misinformation in Tucker Carlson's "The End of Men" about masculinity, hormones, and culture is so dangerous right now.
The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up.
Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
What is a healthy cholesterol level? New study finds high levels of “good cholesterol,” or HDL, may not protect against heart disease, especially for Black adults.
These experts are calling next on these health, fitness, and beauty trends
The treatment, called Xocova, is made by Shionogi & Co., which plans to seek approval from the FDA for its pill in the U.S.
(Reuters) -Merck & Co Inc said on Monday it will acquire cancer drug developer Imago BioSciences Inc for a total equity value of $1.35 billion to expand its portfolio of blood disorder treatments. With Merck's blockbuster cancer immunotherapy Keytruda expected to lose key patents in 2028, the company has been trying to expand its drug portfolio. Last year, it bought Acceleron Pharma for about $11.5 billion to gain access to its experimental therapy for treating a type of high blood pressure.
People with arthritis who take anti-inflammatory medications, like ibuprofen and naproxen, to get relief from painful knees may be harming their joints, a new
Morgan Health, a business unit of financial services company JPMorgan Chase, focuses on employer-sponsored health care.
If you want to save money and still get quality healthcare, consider these options when shopping for your 2023 Medicare Advantage plan.
The widely-held concept that levels of "good" cholesterol in the blood can indicate heart disease risk is not equally true for Blacks and whites, and the measure itself may be of less value than previously thought, according to a U.S. study published on Monday. Various types of cholesterol are thought to have either healthy or unhealthy effects. Low levels of so-called "good" high-density lipoprotein (HDL) cholesterol were linked with higher odds for developing cardiac problems in the long-term study – but only in white participants, the study published in the Journal of the American College of Cardiology found.
Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.
‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort